12Other operating income and expenses
|
millions of CHF |
|
2022 |
|
2021 |
|
Gain from sale of property, plant and equipment |
|
5.5 |
|
1.7 |
|
Operating currency exchange gains, net |
|
– |
|
5.1 |
|
Other operating income |
|
19.2 |
|
27.8 |
|
Total other operating income |
|
24.7 |
|
34.6 |
|
|
|
|
|
|
|
Restructuring expenses |
|
–0.1 |
|
–9.5 |
|
Impairments on tangible and intangible assets |
|
–44.5 |
|
–4.2 |
|
Cost for mergers and acquisitions |
|
–1.5 |
|
–2.7 |
|
Loss from sale of property, plant and equipment |
|
–0.0 |
|
–0.2 |
|
Loss from deconsolidation of subsidiaries |
|
–6.7 |
|
– |
|
Operating currency exchange losses, net |
|
–13.9 |
|
– |
|
Total other operating expenses |
|
–66.7 |
|
–16.5 |
|
|
|
|
|
|
|
Total other operating income / (expenses), net |
|
–42.1 |
|
18.1 |
Other operating income includes income from litigation cases, government grants and incentives, and recharges to third parties not qualifying as sales to customers. In 2022, other operating income included income from charges to the discontinued operation Applicator Systems division (later renamed medmix) for corporate support functions and centrally procured indirect spend utilized by medmix of CHF 9.8 million (2021: CHF 11.5 million).
The loss from deconsolidation of subsidiaries includes a loss of CHF 6.2 million resulting from the deconsolidation of two subsidiaries in Poland and a loss of CHF 0.6 million from the disposal of a subsidiary in Brazil (see note 4).
The group recognized impairments of CHF 44.5 million (2021: CHF 4.2 million). Impairments of CHF 12.1 million (2021: CHF 4.2 million) were recorded based on performed impairment tests on production machines and facilities as well as lease assets. Impairments of CHF 32.4 million on goodwill, other intangible assets, property, plant and equipment and lease assets were recorded in connection with the classification of the business in Russia as held for sale and the write-down to fair value less costs to sell (see note 6).
In 2022, the group recognized restructuring costs of CHF 1.8 million, partially offset with the release of restructuring provisions of CHF 1.7 million. Restructuring costs mainly related to resizing activities in Indonesia.